Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, Perrine Bohner, Francois Crettenand, Sonia-Cristina Rodrigues-Dias, Florence Dartiguenave, Audrey Masnada, Carla Teixeira-Pereira, Sulayman Benmerzoug, Mathieu F Chevalier, Sonia Domingos-Pereira, Sylvain Nguyen, Lenka Polak, Anna K SchneiderSee the full list of authors
14 December 2023
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trialAlex De Caluwe, Emanuela Romano, Philip Poortmans, Andrea Gombos, Elisa Agostinetto, Guilherme Nader Marta, Zoe Denis, Stylianos Drisis, Christophe Vandekerkhove, Antoine Desmet, Catherine Philippson, Ligia Craciun, Isabelle Veys, Denis Larsimont, Marianne PaesmansSee the full list of authors
6 December 2023
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis modelsManali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley
6 December 2023
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinomaMatthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Costa, Patrick Lenehan, Victoire Cardot-Ruffino, Scott Rodig, Kathleen Pfaff, Stephanie K DouganSee the full list of authors
1 December 2023
Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activationHan Zhou, Lei Wang, Zhiwen Lin, Chenwei Jiang, Xingte Chen, Kai Wang, Libin Liu, Lingdong Shao, Jianji Pan, Jinluan Li, Da Zhang, Junxin Wu
30 November 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsTodd M Bauer, Armando Santoro, Chia-Chi Lin, Ignacio Garrido-Laguna, Markus Joerger, Richard Greil, Anna Spreafico, Thomas Yau, Maria-Elisabeth Goebeler, Marie Luise Hütter-Krönke, Antonella Perotti, Pierre-Eric Juif, Darlene Lu, Louise Barys, Viviana CremascoSee the full list of authors
29 November 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, Stefania Gori, Elisabetta Cretella, Massimo Ambroggi, Antonio Frassoldati, Giancarlo Bisagni, Chiara Casarini, Emilio Bria, Luisa Carbognin, Elena Fiorio, Antonella Mura, Claudio Zamagni, Lorenzo GianniSee the full list of authors
28 November 2023
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapyDingpei Han, Yichao Han, Wei Guo, Wei Wei, Su Yang, Jie Xiang, Jiaming Che, Lianggang Zhu, Junbiao Hang, Tom van den Ende, Hanneke W M van Laarhoven, Bin Li, Youqiong Ye, Hecheng Li
28 November 2023
CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinomaRuonan Zhang, Jie Wang, Yu Du, Ze Yu, Yihan Wang, Yixiao Jiang, Yixin Wu, Ting Le, Ziqi Li, Guoqiang Zhang, Lei Lv, Haijie Ma
24 November 2023
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsMarkus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
21 November 2023
